IMCR

Leerink Partners Initiates Coverage of Immunocore Holdings plc - Depositary Receipt () (IMCR) with Outperform Recommendation

Fintel reports that on April 29, 2024, Leerink Partners initiated coverage of Immunocore Holdings plc - Depositary Receipt () (NasdaqGS:IMCR) with a Outperform recommendation.

Analyst Price Forecast Suggests 49.93% Upside

As of April 17, 2024, the average one-year price target for Immunocore Holdings plc - Depositary Receipt () is 87.11. The forecasts range from a low of 63.63 to a high of $96.60. The average price target represents an increase of 49.93% from its latest reported closing price of 58.10.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Immunocore Holdings plc - Depositary Receipt () is 203MM, a decrease of 18.64%. The projected annual non-GAAP EPS is -0.59.

What is the Fund Sentiment?

There are 259 funds or institutions reporting positions in Immunocore Holdings plc - Depositary Receipt (). This is an increase of 25 owner(s) or 10.68% in the last quarter. Average portfolio weight of all funds dedicated to IMCR is 0.49%, an increase of 10.37%. Total shares owned by institutions increased in the last three months by 1.95% to 42,582K shares. IMCR / Immunocore Holdings plc - Depositary Receipt (Common Stock) Put/Call Ratios The put/call ratio of IMCR is 0.21, indicating a bullish outlook.

What are Other Shareholders Doing?

IMCR / Immunocore Holdings plc - Depositary Receipt (Common Stock) Shares Held by Institutions

Rtw Investments holds 6,096K shares representing 12.08% ownership of the company. No change in the last quarter.

Wellington Management Group Llp holds 4,313K shares representing 8.54% ownership of the company. In its prior filing, the firm reported owning 3,913K shares , representing an increase of 9.26%. The firm decreased its portfolio allocation in IMCR by 80.57% over the last quarter.

Price T Rowe Associates holds 2,945K shares representing 5.83% ownership of the company. In its prior filing, the firm reported owning 2,521K shares , representing an increase of 14.38%. The firm increased its portfolio allocation in IMCR by 40.96% over the last quarter.

VGHCX - Vanguard Health Care Fund Investor Shares holds 2,790K shares representing 5.53% ownership of the company. In its prior filing, the firm reported owning 2,086K shares , representing an increase of 25.24%. The firm increased its portfolio allocation in IMCR by 101.19% over the last quarter.

Rock Springs Capital Management holds 2,662K shares representing 5.27% ownership of the company. In its prior filing, the firm reported owning 2,944K shares , representing a decrease of 10.60%. The firm increased its portfolio allocation in IMCR by 9.38% over the last quarter.

Immunocore Holdings Background Information
(This description is provided by the company.)

Immunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. Immunocore’s most advanced oncology therapeutic candidate, tebentafusp, has demonstrated an overall survival benefit in a randomized Phase 3 clinical trial in metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies.

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

Click to Learn More

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.